公开(公告)号：US11603389B2

公开(公告)日：2023-03-14

申请号：US17171295

申请日：2021-02-09

申请人： Janssen Vaccines & Prevention B.V.

发明人： Thierry-Thien Nguyen ,  Mark Bruner

IPC分类号： A61K39/12 ,  A61K39/21 ,  A61K39/39 ,  C07K14/16 ,  A61P31/18 ,  C07K14/005 ,  A61K33/06 ,  A61K39/38 ,  C12N15/09 ,  A61K31/047 ,  A61K31/198 ,  A61K39/00 ,  A61K9/00 ,  A61K47/26 ,  A61K9/08

摘要： Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods for storing the immunogenic compositions.

公开(公告)号：US20230000973A1

公开(公告)日：2023-01-05

申请号：US17808348

申请日：2022-06-23

申请人： Janssen Vaccines & Prevention B.V. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Dan H. Barouch ,  Boris D. Juelg ,  Maria Grazia Pau ,  Frank Tomaka

IPC分类号： A61K39/21 ,  A61K39/42 ,  A61K9/00 ,  A61P31/18 ,  A61P37/04

摘要： Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods involve initial administration of an adenovirus vector vaccine and subsequent administration of a poxvirus vector vaccine, followed by administration of anti-HIV broadly neutralizing antibodies (bNAb).

公开(公告)号：US11517618B2

公开(公告)日：2022-12-06

申请号：US16579193

申请日：2019-09-23

申请人： Janssen Vaccines & Prevention B.V.

发明人： Frank Wegmann ,  Gijs Hardenberg ,  Roland Christian Zahn

IPC分类号： A61K39/00 ,  C07K14/005 ,  A61K39/21 ,  A61K39/12 ,  C12N7/00 ,  C12N15/113 ,  C12N15/861

摘要： Methods of inducing an immune response against human immunodeficiency virus (HIV) are described. In particular, methods of inducing an immune response against HIV by co-locally administering an immunogenically effective amount of an isolated HIV envelope (Env) polypeptide and an immunogenically effective amount of an adenovirus vector encoding an HIV antigen, e.g., Env antigen are described. The isolated HIV Env polypeptide and adenovirus vector can be administered in a single composition or in separate compositions, in which the composition or compositions do not contain an adjuvant.

公开(公告)号：US20220315627A1

公开(公告)日：2022-10-06

申请号：US17805873

申请日：2022-06-08

申请人： Janssen Vaccines & Prevention B.V.

发明人： Lucy Rutten ,  Daphné Truan ,  Nika Mindy Strokappe ,  Johannes Petrus Maria Langedijk

IPC分类号： C07K14/16 ,  A61K39/12 ,  C07K14/005 ,  A61K39/21

摘要： Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.

公开(公告)号：US20220265813A1

公开(公告)日：2022-08-25

申请号：US17651973

申请日：2022-02-22

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes Petrus Maria Langedijk ,  Jaroslaw Juraszek ,  Lucy Rutten

IPC分类号： A61K39/21 ,  A61P31/18 ,  A61P37/04 ,  C12N7/00

摘要： Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.

公开(公告)号：US11338031B2

公开(公告)日：2022-05-24

申请号：US16946485

申请日：2020-06-24

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes Petrus Maria Langedijk ,  Janneke M. Verhagen

IPC分类号： A61K39/12 ,  A61K39/00

摘要： The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).

公开(公告)号：US20220133878A1

公开(公告)日：2022-05-05

申请号：US17579879

申请日：2022-01-20

申请人： Janssen Vaccines & Prevention B.V.

发明人： Myra Noorely WIDJOJOATMODJO ,  Olivier GODEAUX ,  Kristi Lynn WILLIAMS ,  Benoit Christophe Stephan CALLENDRET ,  Jerald C. SADOFF

IPC分类号： A61K39/155 ,  A61P31/14 ,  C12N7/00

摘要： Methods of inducing a safe immune response against respiratory syncytial virus (RSV) in a human subject in need thereof, including administering to the subject a composition including recombinant adenovirus including a nucleic acid encoding an RSV Fusion (F) protein including the amino acid sequence of SEQ ID NO: 1, and a pharmaceutically acceptable carrier, in a total dose of from about 1×101° to about 2×10″ viral particles (vp), are described.

公开(公告)号：US20220125912A1

公开(公告)日：2022-04-28

申请号：US17572097

申请日：2022-01-10

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes Petrus Maria LANGEDIJK ,  Dirk André Emmy ROYMANS

IPC分类号： A61K39/155 ,  A61K39/12 ,  A61P31/14 ,  C07K14/005

摘要： Compositions including a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

公开(公告)号：US20220118081A1

公开(公告)日：2022-04-21

申请号：US17451408

申请日：2021-10-19

申请人： Janssen Vaccines & Prevention B.V.

发明人： Frank WEGMANN ,  Maria Grazia PAU ,  Gijs HARDENBERG ,  Sietske Karla ROSENDAHL HUBER ,  Sanne KROOS

IPC分类号： A61K39/21 ,  A61P31/18

摘要： Methods are described for generating an improved effective immune response against an HIV antigen in humans. The methods comprise administration of a first composition comprising an MVA vector followed by administration of second composition comprising a human adenovirus vector. The methods can be used for the treatment of HIV.

公开(公告)号：US20220111033A1

公开(公告)日：2022-04-14

申请号：US17645556

申请日：2021-12-22

申请人： Janssen Vaccines & Prevention B.V ,  Massachusetts Institute of Technology

发明人： Ronald Vogels ,  Marijn Van Der Neut Kolfschoten ,  Darrell Irvine ,  Ron Weiss ,  Ely Porter ,  Mariane Bandeira Melo ,  Tasuku Kitada

IPC分类号： A61K39/12 ,  C12N15/86 ,  A61K39/00

摘要： Compositions and methods are described for inducing an immune response against an immunogen in humans. The induced immune response is obtained by administering a heterologous prime-boost combination of an in vitro transcribed (IVT) self-replicating RNA (repRNA) and an adenovirus vector. The compositions and methods can be used to provide a protective immunity against a disease, such as a viral infection or a cancer, in humans.